Key Points
- Teladoc CEO Charles III sold 17,805 shares at an average price of $6.10, generating $108,610.50. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 3.68%.
- Teladoc shares opened at $6.51 and were reported as trading up 5.6%; the stock has a market capitalization of approximately $1.18 billion and has traded between $4.40 and $9.89 over the past year.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and a $7.54 price target. Institutional ownership is substantial at 76.82%, while the company continues to report losses and declining year-over-year revenue.
Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) CEO Charles III sold 17,805 shares of the firm's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the sale, the chief executive officer owned 465,535 shares of the company's stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Teladoc Health Trading Up 5.6%
TDOC stock opened at $6.51 on Tuesday. The stock has a market cap of $1.18 billion, a PE ratio of -6.57 and a beta of 2.12. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.89. The company has a 50-day moving average price of $7.46 and a 200 day moving average price of $6.78.
Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The company had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. Sell-side analysts forecast that Teladoc Health, Inc. will post -0.9 EPS for the current year.
Institutional Investors Weigh In On Teladoc Health
A number of hedge funds have recently made changes to their positions in TDOC. Monaco Asset Management SAM bought a new stake in Teladoc Health during the second quarter valued at about $26,864,000. Jupiter Asset Management Ltd. raised its holdings in Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider's stock worth $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP raised its holdings in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after purchasing an additional 1,471,631 shares in the last quarter. Pale Fire Capital SE lifted its position in shares of Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after buying an additional 1,454,288 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Teladoc Health by 512.0% during the second quarter. California State Teachers Retirement System now owns 1,679,701 shares of the health services provider's stock valued at $14,244,000 after buying an additional 1,405,260 shares during the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts recently commented on TDOC shares. Bank of America raised their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Tuesday, July 7th. Citigroup cut their price target on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a research note on Monday, August 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Finally, Canaccord Genuity Group lowered their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Teladoc Health currently has a consensus rating of "Hold" and a consensus target price of $7.54.
Get Our Latest Analysis on TDOC
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.
The company's offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
